[STUDIES ON PHAGOCYTOSIS OF QUARTZ AND CORUNDUM DUSTS BY HUMAN LEUKOCYTES AFTER ADDITION OF ALUMINUM CHLORIDE AS WELL AS QUARTZ DUST WITH CHEMICALLY CHANGED SURFACE].

W. Ulmer,B. Rasche,E. Reif

Abstract:

What problem does this paper attempt to address?

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

Qianqian Wang,Shengjie Jin,Qingyang Zhuang,Na Liu,Ruyi Chen,Salome Adam,Jie Jin,Jing Sun

DOI: https://doi.org/10.1002/mco2.422

2023-01-01

MedComm

Abstract:Chimeric antigen receptor (CAR) T cells have been successfully used in adoptive cell therapy for malignancies. However, some obstacles, including side effects such as graft-versus-host disease and cytokine release syndrome, therapy resistance, limited sources, as well as high cost, limited the application of CAR T cells. Recently, CAR natural killer (NK) cells have been pursued as the effector cells for adoptive immunotherapy for their attractive merits of strong intrinsic antitumor activity and relatively mild side effects. Additionally, CAR NK cells can be available from various sources and do not require strict human leukocyte antigen matching, which suggests them as promising "off-the-shelf" products for clinical application. Although the use of CAR NK cells is restrained by the limited proliferation and impaired efficiency within the immunosuppressive tumor microenvironment, further investigation in optimizing CAR structure and combination therapies will overcome these challenges. This review will summarize the advancement of CAR NK cells, CAR NK cell manufacture, the clinical outcomes of CAR NK therapy, the challenges in the field, and prospective solutions. Besides, we will discuss the emerging application of other immune cells for CAR engineering. Collectively, this comprehensive review will provide a valuable and informative summary of current progress and evaluate challenges and future opportunities of CAR NK cells in tumor treatment.
New antidiabetic therapies: innovative strategies for an old problem

M. Lehrke,N. Marx

DOI: https://doi.org/10.1097/MOL.0b013e328359b19f

IF: 4.616

2012-12-01

Current Opinion in Lipidology

Abstract:Purpose of review Over the last few years, a variety of new antidiabetic drugs have been approved for clinical use and novel agents are currently under development. All of these are facing new regulations created by the demand to not only lower HbA1c but also provide long-term clinical benefit and cardiovascular safety. Recent findings The present review will discuss the following novel therapeutic options: GLP-1 mimetics and DPP-4 inhibitors are new antidiabetic drugs which favourably affect glucose metabolism without a significant risk for hypoglycaemic events and preliminary clinical data suggesting potential beneficial effects with respect to cardiovascular risk reduction. In addition, new antidiabetic concepts include SGLT2 inhibition, dual peroxisome proliferator-activated receptor agonists and G-protein receptor agonists, all of which provide beneficial cardiometabolic characteristics. Summary The development of novel antidiabetic strategies currently does not only focus on potent glucose-lowering properties but also on safety aspects and potential cardiovascular benefits.
Recent advances in CAR-T cells therapy for colorectal cancer

Xiaoling Qin,Fengjiao Wu,Chang Chen,Qi Li

DOI: https://doi.org/10.3389/fimmu.2022.904137

IF: 7.3

2022-09-27

Frontiers in Immunology

Abstract:Colorectal cancer (CRC) is the third most common cancer, with a high mortality rate and a serious impact on people’s life and health. In recent years, adoptive chimeric antigen receptor T (CAR-T) cells therapy has shown well efficacy in the treatment of hematological malignancies, but there are still many problems and challenges in solid tumors such as CRC. For example, the tumor immunosuppressive microenvironment, the low targeting of CAR-T cells, the short time of CAR-T cells in vivo , and the limited proliferation capacity of CAR-T cells, CAR-T cells can not effectively infiltrate into the tumor and so on. New approaches have been proposed to address these challenges in CRC, and this review provides a comprehensive overview of the current state of CAR-T cells therapy in CRC.

immunology
Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities

Xiaotao Jiang,Jiang Xu,Mingfeng Liu,Hui Xing,Zhiming Wang,Lei Huang,Andrew L Mellor,Wei Wang,Sha Wu

DOI: https://doi.org/10.1016/j.canlet.2019.07.017

2019-10-10

Abstract:Cancer immunotherapy is a new and promising option for cancer treatment. Unlike traditional chemo- and radiotherapy, immunotherapy actives host immune system to attack malignancies, and this potentially offers long-term protection from recurrence with less toxicity in comparison to conventional chemo- and radiation therapy. In adoptive CD8+ T cell therapy (ACT), large numbers of tumor-specific T cells are sourced from patients and expanded in vitro and infused back to patients. T cells can be expanded from naturally-induced tumor-specific CD8+ T cells isolated from tumor infiltrating lymphocytes (TIL) or genetically-modified autologous circulating CD8+ T cells. The engineered T cells expressed tumor-specific antigen receptors including chimeric antigen receptors (CARs) and T cell receptors (TCRs), prepared from cultured B and T cell clones, respectively. The most successful ACT, anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy directed against B cell lymphoma, is already approved for use based on evidence of efficacy. Efficacy of solid tumors is not yet forthcoming. This review summarizes current technology developments using ACT in clinical trials. In this review, differences between various ACT approaches are discussed. Furthermore, resistance factors in the tumor microenvironment are also considered, as are immune related adverse effects, critical clinic monitoring parameters and potential mitigation approaches.
Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer

Ke-Tao Jin,Bo Chen,Yu-Yao Liu,H uan-Rong Lan,Jie-Ping Yan

DOI: https://doi.org/10.1186/s12935-021-01763-9

IF: 6.429

2021-02-01

Cancer Cell International

Abstract:Abstract Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer deaths worldwide. Besides common therapeutic approaches, such as surgery, chemotherapy, and radiotherapy, novel therapeutic approaches, including immunotherapy, have been an advent in CRC treatment. The immunotherapy approaches try to elicit patients` immune responses against tumor cells to eradicate the tumor. Monoclonal antibodies (mAbs) and chimeric antigen receptor (CAR) T cells are two branches of cancer immunotherapy. MAbs demonstrate the great ability to completely recognize cancer cell-surface receptors and blockade proliferative or inhibitory pathways. On the other hand, T cell activation by genetically engineered CAR receptor via the TCR/CD3 and costimulatory domains can induce potent immune responses against specific tumor-associated antigens (TAAs). Both of these approaches have beneficial anti-tumor effects on CRC. Herein, we review the different mAbs against various pathways and their applications in clinical trials, the different types of CAR-T cells, various specific CAR-T cells against TAAs, and their clinical use in CRC treatment.

oncology
Immunotherapies catering to the unmet medical need of cold colorectal cancer

Jun Yuan,Jiarui Li,Ce Gao,Chun Jiang,Ze Xiang,Jian Wu

DOI: https://doi.org/10.3389/fimmu.2022.1022190

IF: 7.3

2022-01-01

Frontiers in Immunology

Abstract:As a common malignant tumor of gastrointestinal tract, the incidence of colorectal cancer (CRC) has gradually increased in recent years. In western developed countries, it has even become the second largest malignant tumor next to lung cancer. Immunotherapy is a hot topic in the field of cancer therapy, including immune checkpoint blockade (ICB), adoptive cell therapy (ACT), cancer vaccines and cytokines, aiming to improve the ability of the immune system to recognize, target and eliminate cancer cells. However, cold CRC, which accounts for a high proportion of CRC, is not so reactive to it. The development of immunotherapy to prevent cancer cells from forming "immune escape" pathways to the immune system in cold CRC, has been under increasing study attention. There is proof that an organic combination of radiotherapy, chemotherapy, and several immunotherapies can considerably boost the immune system's capacity to eradicate tumor cells. In this review, we summarized the role of immunotherapy in colorectal cancer. In addition, we propose a breakthrough and strategy to improve the role of immunotherapy in cold CRC based on its characteristics.
CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Ping Ren,Chuyue Zhang,Wenping Li,Xian Wang,Aibing Liang,Guang Yang,Hongtao Xu,Peixiang Ma

DOI: https://doi.org/10.1002/adbi.202101262

2022-01-01

Advanced Biology

Abstract:Chimeric antigen receptors (CAR) redirect T cells to specifically recognize and eliminate tumor cells. CAR-T therapy has achieved successful clinical outcomes, and it has been transformed into commercially available products to treat acute lymphoblastic leukemia and B cell lymphoma. These breakthroughs have motivated hundreds of CAR-T clinical trials initiated each year, with ≈900 cases registered on the ClinicalTrials website till 2021. Accumulating clinical experiences have highlighted some limitations of this strategy, e.g., relapse after complete response, poor efficacy in solid tumors, on-target off-tumor toxicities, lack of persistence, and tumor resistance. These challenges limit the therapeutic application of CAR-T cells. Multidisciplinary approaches are actively investigated to address these issues. In this review, the antigens, CAR designs, and cell sources are summarized in clinical trials from 2020 to 2021. The innovative modular and programmable designs in CAR-T cells, including advances in signaling domains, antigen-recognition domains, T cell engineering, and cell resources, are further discussed. Integrative genetic and chemical engineering strategies are promising to improve the versatility, antitumor efficacy, persistence, and safety of CAR-T cells. In the future, the next generation of CAR-T cell therapies will offer more options for patients who are refractory to standard tumor therapies.
Changing Patterns of Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Narrative Review

Weijing He,Qingguo Li,Xinxiang Li

DOI: https://doi.org/10.1016/j.critrevonc.2022.103885

IF: 6.625

2023-01-01

Critical Reviews in Oncology/Hematology

Abstract:Standard treatment for patients with locally advanced rectal cancer has been the multidisciplinary approach of neoadjuvant chemoradiotherapy, followed by total mesorectal excision (TME) and postoperative adjuvant chemotherapy. This reduces the local recurrence rate, but the challenge of distant metastasis still persists. The improvement in treatment approach has always been the focus of clinical research and studies have been conducted worldwide in recent years. On one hand, evidence suggests that increasing the intensity of treatment can result in better tumor regression, for example by adding a second drug to the neoadjuvant chemoradiotherapy, or extending the interval between neoadjuvant therapy and surgery, or incorporating chemotherapy and chemoradiotherapy in the neoadjuvant setting. On the other hand, neoadjuvant immunotherapy and selective omission of neoadjuvant radiotherapy may improve the quality of life of patients. In this article, we review the key clinical research progresses in neoadjuvant therapy for locally advanced rectal cancer, hoping to provide some valuable views on the individualized treatment for rectal cancer.
TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals

Francesco Manfredi,Beatrice Claudia Cianciotti,Alessia Potenza,Elena Tassi,Maddalena Noviello,Andrea Biondi,Fabio Ciceri,Chiara Bonini,Eliana Ruggiero

DOI: https://doi.org/10.3389/fimmu.2020.01689

IF: 7.3

2020-09-03

Frontiers in Immunology

Abstract:Adoptive T cell therapy (ACT) is a rapidly evolving therapeutic approach designed to harness T cell specificity and function to fight diseases. Based on the evidence that T lymphocytes can mediate a potent anti-tumor response, initially ACT solely relied on the isolation, <i>in vitro</i> expansion, and infusion of tumor-infiltrating or circulating tumor-specific T cells. Although effective in a subset of cases, in the first ACT clinical trials several patients experienced disease progression, in some cases after temporary disease control. This evidence prompted researchers to improve ACT products by taking advantage of the continuously evolving gene engineering field and by improving manufacturing protocols, to enable the generation of effective and long-term persisting tumor-specific T cell products. Despite recent advances, several challenges, including prioritization of antigen targets, identification, and optimization of tumor-specific T cell receptors, in the development of tools enabling T cells to counteract the immunosuppressive tumor microenvironment, still need to be faced. This review aims at summarizing the major achievements, hurdles and possible solutions designed to improve the ACT efficacy and safety profile in the context of liquid and solid tumors.

immunology
Challenges of chimeric antigen receptor-T/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies

Haifeng Wang,Weihuo Pan

DOI: https://doi.org/10.1007/s11010-022-04568-0

IF: 3.842

2022-10-04

Molecular and Cellular Biochemistry

Abstract:Colorectal cancer (CRC) is the second most common cancer globally and one of the deadliest human malignancies. Traditional therapies, such as surgery, chemotherapy, and combination therapies have been used to treat patients with CRC. However, recently immunotherapy has been considered a practical and attractive therapeutic approach in various cancers, such as CRC. Among the immunotherapy methods, chimeric antigen receptor (CAR)-T, and CAR-natural killer cells (NK) cells therapy have been significantly successful, mainly in treating hematological malignancies. However, the effectiveness of CAR-T/NK cell therapy in the treatment of solid tumors, such as CRC has been less than blood malignancies due to various challenges, such as the selection of tumor antigens, lack of proper trafficking in tumor tissue, immunosuppressive tumor microenvironment, tumor heterogeneity and, adverse effects during and after CAR-T/NK cell therapy. This review summarized the biological structure of CAR-T/NK cells and their use in various types of human malignancies, particularly CRC, as well as the challenges of this type of treatment and the outcome of related combination therapies.

cell biology
Challenges and new technologies in adoptive cell therapy

Pengchao Zhang,Guizhong Zhang,Xiaochun Wan

DOI: https://doi.org/10.1186/s13045-023-01492-8

IF: 28.5

2023-08-20

Journal of Hematology & Oncology

Abstract:Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and chimeric antigen receptor (CAR)-T cell therapies, many novel strategies for cancer treatment have been developed. Owing to its promising outcomes, CAR-T cell therapy has revolutionized the field of ACTs, particularly for hematologic malignancies. Despite these advances, CAR-T cell therapy still has limitations in both autologous and allogeneic settings, including practicality and toxicity issues. To overcome these challenges, researchers have focused on the application of CAR engineering technology to other types of immune cell engineering. Consequently, several new cell therapies based on CAR technology have been developed, including CAR-NK, CAR-macrophage, CAR-γδT, and CAR-NKT. In this review, we describe the development, advantages, and possible challenges of the aforementioned ACTs and discuss current strategies aimed at maximizing the therapeutic potential of ACTs. We also provide an overview of the various gene transduction strategies employed in immunotherapy given their importance in immune cell engineering. Furthermore, we discuss the possibility that strategies capable of creating a positive feedback immune circuit, as healthy immune systems do, could address the flaw of a single type of ACT, and thus serve as key players in future cancer immunotherapy.

oncology,hematology
The Semiology Of Changing Brand Image The Semiology of Changing Brand Image 1-24

I. Combe,D. Crowther

Abstract:This article considers the attempted change to the image of an established brand by studying the semiotics within the brand’s historical advertising campaigns. The use of semiotics to study the interpretation of messages is discussed, and the link between interpretation of messages and advertising effectiveness in changing brand image is explored. The authors deconstruct advertisements of a brand to provide a model containing opposing dialectics that may aid managers by highlighting alternative symbolic messages contained in advertisements. Once identified, these alternative symbolic messages may be used to help change brand image and influence advertising effectiveness. Although the study focuses upon a major brand of beer, this is an industry in which there are numerous small firms, and many of those have constrained marketing budgets, and thus need to make sure that their advertising is effective. Equally, entrepreneurial marketing is not to found only in the small firm, and the case study discusses a radical and imaginative brand repositioning of a well established product.
Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T

Qiaofei Liu,Jiayi Li,Huaijin Zheng,Sen Yang,Yuze Hua,Nan Huang,Jorg Kleeff,Quan Liao,Wenming Wu

DOI: https://doi.org/10.1186/s12943-023-01735-9

IF: 37.3

2023-02-07

Molecular Cancer

Abstract:In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-T) therapy are two milestone achievements in clinical immunotherapy. However, both show limited efficacies in most solid neoplasms, which necessitates the exploration of new immunotherapeutic modalities. The failure of CAR-T and immune checkpoint blockade in several solid neoplasms is attributed to multiple factors, including low antigenicity of tumor cells, low infiltration of effector T cells, and diverse mechanisms of immunosuppression in the tumor microenvironment. New adoptive cell therapies have been attempted for solid neoplasms, including TCR-T, CAR-natural killer cells (CAR-NK), and CAR-macrophages (CAR-M). Compared to CAR-T, these new adoptive cell therapies have certain advantages in treating solid neoplasms. In this review, we summarized the 40-year evolution of adoptive cell therapies, then focused on the advances of TCR-T, CAR-NK, and CAR-M in solid neoplasms and discussed their potential clinical applications.

oncology,biochemistry & molecular biology
Adoptive Immunotherapy beyond CAR T-Cells

Aleksei Titov,Ekaterina Zmievskaya,Irina Ganeeva,Aygul Valiullina,Alexey Petukhov,Aygul Rakhmatullina,Regina Miftakhova,Michael Fainshtein,Albert Rizvanov,Emil Bulatov

DOI: https://doi.org/10.3390/cancers13040743

2021-02-11

Cancers

Abstract:Adoptive cell immunotherapy (ACT) is a vibrant field of cancer treatment that began progressive development in the 1980s. One of the most prominent and promising examples is chimeric antigen receptor (CAR) T-cell immunotherapy for the treatment of B-cell hematologic malignancies. Despite success in the treatment of B-cell lymphomas and leukemia, CAR T-cell therapy remains mostly ineffective for solid tumors. This is due to several reasons, such as the heterogeneity of the cellular composition in solid tumors, the need for directed migration and penetration of CAR T-cells against the pressure gradient in the tumor stroma, and the immunosuppressive microenvironment. To substantially improve the clinical efficacy of ACT against solid tumors, researchers might need to look closer into recent developments in the other branches of adoptive immunotherapy, both traditional and innovative. In this review, we describe the variety of adoptive cell therapies beyond CAR T-cell technology, i.e., exploitation of alternative cell sources with a high therapeutic potential against solid tumors (e.g., CAR M-cells) or aiming to be universal allogeneic (e.g., CAR NK-cells, γδ T-cells), tumor-infiltrating lymphocytes (TILs), and transgenic T-cell receptor (TCR) T-cell immunotherapies. In addition, we discuss the strategies for selection and validation of neoantigens to achieve efficiency and safety. We provide an overview of non-conventional TCRs and CARs, and address the problem of mispairing between the cognate and transgenic TCRs. Finally, we summarize existing and emerging approaches for manufacturing of the therapeutic cell products in traditional, semi-automated and fully automated Point-of-Care (PoC) systems.

oncology
Adoptive Cell Therapy of Gastric Cancer

Zhengyun Zou,Lianjun Zhao,Yu Ren,Shiyao Du

DOI: https://doi.org/10.1007/978-981-10-3978-2_11

2017-01-01

Abstract:Tremendous progress has been made in the field of immunotherapy through various research studies and clinical trials. This work has led to significant breakthroughs in the treatment of malignant tumors. Immunotherapy treatment is an additional treatment option to other novel approaches, including immune checkpoint inhibitors and signaling pathway inhibitors; those have demonstrated clear efficacy in the treatment of numerous cancer types. Some examples include malignant melanoma, kidney cancer, lung cancer, and urinary bladder cancer. Adoptive cell therapy (ACT) has also shown clear effects in the treatment of different malignant diseases. ACT is a highly personalized cancer therapy that takes advantage of immune cells that infiltrate tumors for direct anticancer activities. ACT utilizes either natural host cells, such as lymphokine-activated killer cells (LAK), cytokine-induced killer cells (CIK), tumor-infiltrating lymphocytes (TIL), and cytotoxic T lymphocytes (CTL), or host cells that have been genetically engineered to possess antitumor T cell receptors (TCRs) or chimeric antigen receptors (CARs). This chapter profiles ACT in cancer immunotherapy based on reliable data, some of which demonstrates the use of this cell therapy for the treatment of gastric cancer.
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma

Jingjing Pu,Ting Liu,Amit Sharma,Liping Jiang,Feng Wei,Xiubao Ren,Ingo G. H. Schmidt-Wolf,Jian Hou

DOI: https://doi.org/10.1186/s40164-024-00576-6

2024-10-31

Experimental Hematology and Oncology

Abstract:The basic idea of modulating the immune system to better recognize and fight tumor cells has led to the successful introduction of adoptive cellular immunotherapy (ACT). ACT-based treatment regimens, in which the patient's own immune cells are isolated and subsequently expanded (ex vivo) and reinfused, have also contributed significantly to the development of a personalized treatment strategy. Complementing this, the unprecedented advances in ACTs as chimeric antigen receptor (CAR)-T cell therapies and their derivatives such as CAR-NK, CAR-macrophages, CAR-γδT and CAR-NKT have further maximized the therapeutic outcomes. Herein, we provide a comprehensive overview of the development of ACTs in multiple myeloma (MM) and outline how they have evolved from an experimental form to a mainstay of standard clinical settings. Besides, we provide insights into cytokine-induced killer cell (CIK) therapy, an alternative form of ACT that (as CIK or CAR-CIK) has enormous potential in the clinical spectrum of MM. We also summarize the results of the major preclinical and clinical studies of adoptive cell therapy in MM and address the current challenges (such as cytokine release syndrome (CRS) and neurotoxicity) that limit its complete success in the cancer landscape.

oncology,hematology
New immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses

Amin Kamrani,Hadi Nasiri,Ali Hassanzadeh,Javad Ahmadian Heris,Reza Mohammadinasab,Shahram Sadeghvand,Mohammadreza Sadeghi,Zahra Valedkarimi,Ramin Hosseinzadeh,Navid Shomali,Morteza Akbari

DOI: https://doi.org/10.1186/s12964-023-01430-8

IF: 7.525

2024-01-20

Cell Communication and Signaling

Abstract:Colorectal cancer is one of the most common causes of mortality worldwide. There are several potential risk factors responsible for the initiation and progression of colorectal cancer, including age, family history, a history of inflammatory bowel disease, and lifestyle factors such as physical activity and diet. For decades, there has been a vast amount of study on treatment approaches for colorectal cancer, which has led to conventional therapies such as chemotherapy, surgery, etc. Considering the high prevalence and incidence rate, scholars believe there is an urgent need for an alternative, more efficacious treatment with fewer adverse effects than the abovementioned treatments. Immunotherapy has emerged as a potential treatment alternative in a few years and has become one of the fastest-evolving therapeutic methods. Immunotherapy works by activating or enhancing the immune system's power to identify and attack cancerous cells. This review summarizes the most crucial new immunotherapy methods under investigation for colorectal cancer treatment, including Immune checkpoint inhibitors, CAR-T cell therapy, BiTEs, Tumor-infiltrating lymphocytes, and Oncolytic virus therapy. Furthermore, this study discusses the application of combination therapy, precision medicine, biomarker discovery, overcoming resistance, and immune-related adverse effects.

cell biology
Enhanced cellular therapy: revolutionizing adoptive cellular therapy

Meng-Yao Xu,Na Zeng,Chen-Qian Liu,Jian-Xuan Sun,Ye An,Si-Han Zhang,Jin-Zhou Xu,Xing-Yu Zhong,Si-Yang Ma,Hao-Dong He,Jia Hu,Qi-Dong Xia,Shao-Gang Wang

DOI: https://doi.org/10.1186/s40164-024-00506-6

2024-04-28

Experimental Hematology and Oncology

Abstract:Enhanced cellular therapy has emerged as a novel concept following the basis of cellular therapy. This treatment modality applied drugs or biotechnology to directly enhance or genetically modify cells to enhance the efficacy of adoptive cellular therapy (ACT). Drugs or biotechnology that enhance the killing ability of immune cells include immune checkpoint inhibitors (ICIs) / antibody drugs, small molecule inhibitors, immunomodulatory factors, proteolysis targeting chimera (PROTAC), oncolytic virus (OV), etc. Firstly, overcoming the inhibitory tumor microenvironment (TME) can enhance the efficacy of ACT, which can be achieved by blocking the immune checkpoint. Secondly, cytokines or cytokine receptors can be expressed by genetic engineering or added directly to adoptive cells to enhance the migration and infiltration of adoptive cells to tumor cells. Moreover, multi-antigen chimeric antigen receptors (CARs) can be designed to enhance the specific recognition of tumor cell-related antigens, and OVs can also stimulate antigen release. In addition to inserting suicide genes into adoptive cells, PROTAC technology can be used as a safety switch or degradation agent of immunosuppressive factors to enhance the safety and efficacy of adoptive cells. This article comprehensively summarizes the mechanism, current situation, and clinical application of enhanced cellular therapy, describing potential improvements to adoptive cellular therapy.

oncology,hematology
Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy

Taxiarchis Konstantinos Nikolouzakis,Emmanuel Chrysos,Anca Oana Docea,Persefoni Fragkiadaki,John Souglakos,John Tsiaoussis,Aristidis Tsatsakis

DOI: https://doi.org/10.3390/cancers16111995

2024-05-25

Cancers

Abstract:Cancer of the colon and rectum (CRC) has been identified among the three most prevalent types of cancer and cancer-related deaths for both sexes. Even though significant progress in surgical and chemotherapeutic techniques has markedly improved disease-free and overall survival rates in contrast to those three decades ago, recent years have seen a stagnation in these improvements. This underscores the need for new therapies aiming to augment patient outcomes. A number of emerging strategies, such as immune checkpoint inhibitors (ICIs) and adoptive cell therapy (ACT), have exhibited promising outcomes not only in preclinical but also in clinical settings. Additionally, a thorough appreciation of the underlying biology has expanded the scope of research into potential therapeutic interventions. For instance, the pivotal role of altered telomere length in early CRC carcinogenesis, leading to chromosomal instability and telomere dysfunction, presents a promising avenue for future treatments. Thus, this review explores the advancements in CRC immunotherapy and telomere-targeted therapies, examining potential synergies and how these novel treatment modalities intersect to potentially enhance each other's efficacy, paving the way for promising future therapeutic advancements.

oncology
Adoptive T cell therapy for solid tumors: current landscape and future challenges

Víctor Albarrán,María San Román,Javier Pozas,Jesús Chamorro,Diana Isabel Rosero,Patricia Guerrero,Juan Carlos Calvo,Carlos González,Coral García de Quevedo,Patricia Pérez de Aguado,Jaime Moreno,Alfonso Cortés,Ainara Soria

DOI: https://doi.org/10.3389/fimmu.2024.1352805

IF: 7.3

2024-03-14

Frontiers in Immunology

Abstract:Adoptive cell therapy (ACT) comprises different strategies to enhance the activity of T lymphocytes and other effector cells that orchestrate the antitumor immune response, including chimeric antigen receptor (CAR) T-cell therapy, T-cell receptor (TCR) gene-modified T cells, and therapy with tumor-infiltrating lymphocytes (TILs). The outstanding results of CAR-T cells in some hematologic malignancies have launched the investigation of ACT in patients with refractory solid malignancies. However, certain characteristics of solid tumors, such as their antigenic heterogeneity and immunosuppressive microenvironment, hamper the efficacy of antigen-targeted treatments. Other ACT modalities, such as TIL therapy, have emerged as promising new strategies. TIL therapy has shown safety and promising activity in certain immunogenic cancers, mainly advanced melanoma, with an exciting rationale for its combination with immune checkpoint inhibitors. However, the implementation of TIL therapy in clinical practice is hindered by several biological, logistic, and economic challenges. In this review, we aim to summarize the current knowledge, available clinical results, and potential areas of future research regarding the use of T cell therapy in patients with solid tumors

immunology

[STUDIES ON PHAGOCYTOSIS OF QUARTZ AND CORUNDUM DUSTS BY HUMAN LEUKOCYTES AFTER ADDITION OF ALUMINUM CHLORIDE AS WELL AS QUARTZ DUST WITH CHEMICALLY CHANGED SURFACE].

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

New antidiabetic therapies: innovative strategies for an old problem

Recent advances in CAR-T cells therapy for colorectal cancer

Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities

Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer

Immunotherapies catering to the unmet medical need of cold colorectal cancer

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Changing Patterns of Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Narrative Review

TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals

Challenges of chimeric antigen receptor-T/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies

Challenges and new technologies in adoptive cell therapy

The Semiology Of Changing Brand Image The Semiology of Changing Brand Image 1-24

Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T

Adoptive Immunotherapy beyond CAR T-Cells

Adoptive Cell Therapy of Gastric Cancer

Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma

New immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses

Enhanced cellular therapy: revolutionizing adoptive cellular therapy

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy

Adoptive T cell therapy for solid tumors: current landscape and future challenges